Atea Pharmaceuticals, Inc.
AVIR
$6.00
$0.091.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 121.62M | 95.18M | 77.24M | 68.09M | 70.63M |
| Gross Profit | -121.62M | -95.18M | -77.24M | -68.09M | -70.63M |
| SG&A Expenses | 32.86M | 39.10M | 42.93M | 46.08M | 48.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 180.63M | 160.42M | 146.31M | 140.31M | 171.08M |
| Operating Income | -180.63M | -160.42M | -146.31M | -140.31M | -171.08M |
| Income Before Tax | -164.51M | -146.19M | -135.27M | -138.59M | -167.46M |
| Income Tax Expenses | -6.16M | 831.00K | 861.00K | 897.00K | 925.00K |
| Earnings from Continuing Operations | -158.35 | -147.03 | -136.13 | -139.49 | -168.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -158.35M | -147.03M | -136.13M | -139.49M | -168.39M |
| EBIT | -180.63M | -160.42M | -146.31M | -140.31M | -171.08M |
| EBITDA | -180.22M | -160.01M | -145.89M | -139.90M | -170.66M |
| EPS Basic | -1.95 | -1.78 | -1.61 | -1.65 | -2.00 |
| Normalized Basic EPS | -1.27 | -1.07 | -0.93 | -0.86 | -1.08 |
| EPS Diluted | -1.95 | -1.78 | -1.61 | -1.65 | -2.00 |
| Normalized Diluted EPS | -1.27 | -1.07 | -0.93 | -0.86 | -1.08 |
| Average Basic Shares Outstanding | 326.09M | 332.42M | 337.79M | 338.30M | 337.06M |
| Average Diluted Shares Outstanding | 326.09M | 332.42M | 337.79M | 338.30M | 337.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |